AstraZeneca acquires St. Louis vaccine biotech Omniose

AstraZeneca has acquired Omniose, a St. Louis-based preclinical biotechnology company, making it a wholly owned subsidiary within AstraZeneca's Infectious Disease Unit. The deal follows a three-year exclusive research collaboration between the two companies. Financial terms were not disclosed.

Omniose's proprietary bioconjugation platform is designed for bacterial polysaccharide conjugate vaccines. The technology allows vaccine components to be produced and linked within a single cell, which could simplify manufacturing and improve molecular precision.

AstraZeneca plans to use the platform to support vaccine development against serious bacterial infections, including those complicated by antimicrobial resistance.